BioPharmaSpec Announces Expansion
News Mar 22, 2016
BioPharmaSpec has announced it is expanding its business in Asia with business development teams in India and the Asia Pacific region. This will allow scientists in the region to access BioPharmaSpec’s cost-effective, efficient characterization strategies and help accelerate the development of their biosimilars.
BioPharmaSpec’s new business development teams will offer scientists in Asia access to technical experts, who will detail how the company’s unrivalled expertise in mass spectrometry can be used to characterize critical features of biologics, providing them with a competitive edge for their biosimilar development.
Having already established relationships with major Asian firms developing biosimilars for the global market, BioPharmaSpec operates to robust quality standards, allowing full traceability without the associated costs of a Good Manufacturing Practice (GMP) system (which is not required for the early-stage characterization and comparability of biosimilars). The company also provides Asian biopharma firms with a clear understanding of what types of analysis and documentation are necessary to meet the stringent requirements of European and US regulators.
To support the expansion into Asia, CEO Dr. Andrew J. Reason is presenting at BioPharma Asia in Singapore on 22–24 March, 2016 with a session entitled “Structural Characterization of Monoclonal Antibodies and Antibody Drug Conjugates”. The presentation will focus on how mass spectrometry and other techniques are employed to characterize biopharmaceutical products and will present several interesting case studies, including examples of biosimilar development.
“The structural characterization of biopharmaceutical products is a broad and complicated process and a wide variety of techniques are involved in providing full characterization information. For these reasons, I believe that our industry values proven technical expertise and product experience when selecting a CRO partner, especially when important decisions relating to comparability or biosimilarity are to be made”, commented BioPharmaSpec Founder and CEO Dr. Andrew J. Reason. “I look forward to presenting on how BioPharmaSpec scientists use technical and instrumentation expertise built up over 35 years to provide quality analytical data that our clients can rely on.”
Dr. Reason added, “We are an international CRO, performing a comprehensive range of characterization services from fully-equipped, modern laboratories in both the UK and USA. Asia is an important aspect of our expansion plans and we encourage BioPharma Asia delegates to visit us at Exhibition Space C12 or contact us directly through our website, where our new business development team will be pleased to discuss development projects and characterization requirements.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018